For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Development of anticipatory nausea: a prospective analysis.
The development of anticipatory nausea in cancer chemotherapy typically has been viewed in terms of a respondent learning model . Firm support for this etiological model has been precluded by use of retrospective research design s , however . The present study employed a prospect i ve design to identify patient and treatment-related variables characteristic of patients who subsequently develop anticipatory nausea . Seventy-one chemotherapy out patients were interviewed before and after each chemotherapy infusion during their first 6 months of treatment . Hierarchical multiple regression analysis revealed that patients who developed anticipatory nausea were characterized by more severe posttreatment nausea , more time-consuming treatment infusions , and greater state anxiety relative to patients without anticipatory nausea . In general , results supported a respondent learning conceptualization of the development of anticipatory nausea . Clinical implication s of these findings for the prevention of anticipatory nausea are suggested
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .